B. Tweedy, Ch. Browne
Tweedy, Browne Co All Funds (US)
Tweedy, Browne Co All Funds (US) Ligand Pharmaceuticals Incorporated stake
total: 185
Tweedy, Browne Co All Funds (US) LGND trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2025 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2025 Q3
According to 2026 Q2 report, Tweedy, Browne Co All Funds (US) doesn't hold any Ligand Pharmaceuticals Incorporated (LGND) shares. To date, the estimated cost basis is nearly $113.68 for "buy" trades and estimated average "sell" price is $113.68. Tweedy, Browne Co All Funds (US) first purchased LGND in 2025 Q2, initially acquiring 3,140 shares. Since the initial investment in Ligand Pharmaceuticals Incorporated (LGND), Tweedy, Browne Co All Funds (US) has made 1 more transaction.
When did Tweedy, Browne Co All Funds (US) sell Ligand Pharmaceuticals Incorporated (LGND)?
Tweedy, Browne Co All Funds (US) sold off the entire Ligand Pharmaceuticals Incorporated (LGND) position in 2025 Q3.
When did Tweedy, Browne Co All Funds (US) buy Ligand Pharmaceuticals Incorporated (LGND)?
Tweedy, Browne Co All Funds (US) first invested in Ligand Pharmaceuticals Incorporated (LGND) in 2025 Q2 at the reported quarter-end price of $113.68 per share.
What's the cost basis of Tweedy, Browne Co All Funds (US)'s LGND stake?
The estimated cost basis for Ligand Pharmaceuticals Incorporated (LGND) stake is around $113.68 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $113.68
- Weighted AVG sell price:
- $113.68
Tweedy, Browne Co All Funds (US)'s historical trades in Ligand Pharmaceuticals Incorporated
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q3
|
0.00%
|
0
|
$113.68
|
|
-100% (-3,140)
|
-0.03%
|
|
2025 Q2
|
0.03%
|
3,140
|
$113.68
|
$356,955
|
new
|
+0.03%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.